<DOC>
	<DOC>NCT00397826</DOC>
	<brief_summary>To collect lipid-lowering response data with the use of simvastatin 40 mg tablet in patients with hypercholesterolemia.</brief_summary>
	<brief_title>Evaluation of the Effects of Simvastatin 40mg</brief_title>
	<detailed_description>This is an open-label, prospective study to investigate lipid-lowering efficacy and sympathetic response of normotensive hypercholesterolemia patients after receiving simvastatin 40 mg once daily for 3 months. The total duration of the study will be approximately 13 weeks, comprising of a 1-week (or 4 weeks?) screening period and a 12-week active treatment period. 20 hypercholesterolemia patients with normal blood pressure will be enrolled into treatment group.</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Male or female patient, &gt;18 years of age Patients with hypercholesterolemia who meet the following lipid criteria: 1. primary cholesterolemia: total cholesterol&gt;=240 mg/dl or ldlc &gt;= 160 mg/dl 2. secondary cholesterolemia (patients with cad, dm): ldlc&gt;=130 mg/dl The patient is willing to follow an NCEP therapeutic lifestyle changes (tlc) or similar cholesterollowering diet throughout the duration of the study Congestive heart failure (NYHA class III or IV), uncontrolled cardiac arrhythmia, unstable angina Hypertension (based on the atp 3 guidelines) Taking potent lipidlowering agents Unstable diabetes (hba1c &gt;9%) or newly diagnosed (within 3 months), or a change in antidiabetes medications within 3 months of screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>